Hemispherian Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Private

  • Employees
  • 11

Employees

  • Latest Deal Type
  • Later Stage VC

  • Investors
  • 11

Hemispherian General Information

Description

Operator of a biotechnology company intended to develop treatments for aggressive types of cancer. The company engages in developing personalized cancer therapies to fight glioblastoma multiforme tumors and is developing a novel class of small-molecule drugs, enabling physicians to get access to novel drugs in areas of unmet medical need.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Lørenveien 73
  • 0585 Oslo
  • Norway
+47 40
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Vertical(s)
Corporate Office
  • Lørenveien 73
  • 0585 Oslo
  • Norway
+47 40

Hemispherian Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Hemispherian Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
9. Later Stage VC 01-Jun-2024 Completed Pre-Clinical Trials
8. Grant 15-Dec-2023 Completed Pre-Clinical Trials
7. Later Stage VC (Series A1) 24-Nov-2022 Completed Pre-Clinical Trials
6. Grant 15-Jun-2022 Completed Pre-Clinical Trials
5. Seed Round 03-May-2022 Completed Pre-Clinical Trials
4. Seed Round 04-Jan-2021 Completed Pre-Clinical Trials
3. Grant 28-Sep-2020 Completed Pre-Clinical Trials
2. Grant 12-Jun-2020 $133K Completed Pre-Clinical Trials
1. Accelerator/Incubator Completed Startup
To view Hemispherian’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Hemispherian Patents

Hemispherian Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2024261243-A1 Combination comprising a deoxycytidine derivative and a parp inhibitor for use in a method of treating hr proficient cancer Inactive 21-Jun-2023
GB-201917499-D0 Methods of synthesis Inactive 29-Nov-2019
GB-201901427-D0 Cancer therapies Active 01-Feb-2019
GB-2580963-A Cancer therapies Active 01-Feb-2019
GB-2580963-B Cancer therapies Active 01-Feb-2019 A61K31/7068
To view Hemispherian’s complete patent history, request access »

Hemispherian Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Hemispherian Investors (11)

Investor Name Investor Type Holding Investor Since Participating Rounds
Locapes Investment Fund Venture Capital Minority
Kistefos PE/Buyout Minority
Kvantia Hedge Fund Minority
Angel (individual) Minority
European Innovation Council Accelerator/Incubator Minority
You’re viewing 5 of 11 investors. Get the full list »

Hemispherian Investments (1)

Hemispherian’s most recent deal was a Joint Venture with GLIX1. The deal was made on 29-Sep-2025.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
GLIX1 29-Sep-2025 Joint Venture Drug Discovery
To view Hemispherian’s complete investments history, request access »

Hemispherian FAQs

  • When was Hemispherian founded?

    Hemispherian was founded in 2015.

  • Where is Hemispherian headquartered?

    Hemispherian is headquartered in Oslo, Norway.

  • What is the size of Hemispherian?

    Hemispherian has 11 total employees.

  • What industry is Hemispherian in?

    Hemispherian’s primary industry is Drug Discovery.

  • Is Hemispherian a private or public company?

    Hemispherian is a Private company.

  • What is Hemispherian’s current revenue?

    The current revenue for Hemispherian is .

  • How much funding has Hemispherian raised over time?

    Hemispherian has raised $4.7M.

  • Who are Hemispherian’s investors?

    Locapes Investment Fund, Kistefos, Kvantia, , and European Innovation Council are 5 of 11 investors who have invested in Hemispherian.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process